<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03239873</url>
  </required_header>
  <id_info>
    <org_study_id>V210-A03</org_study_id>
    <nct_id>NCT03239873</nct_id>
  </id_info>
  <brief_title>Evaluation of Immunogenicity and Safety of VARIVAX™ Passage Extension 34 (PE34) Process in Children (V210-A03)</brief_title>
  <official_title>A Phase 3, Double-Blind, Randomized, Multicenter, Controlled Study to Evaluate the Immunogenicity, Safety, and Tolerability of VARIVAX™ Passage Extension 34 (PE34) Process Administered Concomitantly With M-M-R™ II</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the immunogenicity, safety, and tolerability of VARIVAX™ (Varicella
      Virus Vaccine Live) manufactured with a new passage extension (PE34) process compared with
      the VARIVAX™ 2016 commercial process. The primary hypotheses being tested are that antibody
      response rate and mean antibody titer induced at 6 weeks after a single vaccination by
      VARIVAX™ PE34 Process are non-inferior to those induced by VARIVAX™ 2016 commercial process,
      and that antibody response rate induced by VARIVAX™ PE34 Process is acceptable.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 17, 2017</start_date>
  <completion_date type="Anticipated">April 19, 2019</completion_date>
  <primary_completion_date type="Anticipated">October 9, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Varicella Zoster Virus (VZV) Antibody Response Rate</measure>
    <time_frame>6 weeks (43 days) after Vaccination 1</time_frame>
    <description>The percentage of participants with VZV antibody levels &gt;=5 glycoprotein enzyme-linked immunosorbent Assay (gpELISA) units/mL will be assessed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Varicella Zoster Virus (VZV) Geometric Mean Titer</measure>
    <time_frame>6 weeks (43 days) after Vaccination 1</time_frame>
    <description>The geometric mean titer of VZV antibodies will be assessed.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Elevated Temperature</measure>
    <time_frame>Up to 42 days after Vaccination 1 and Vaccination 2 (up to 133 days)</time_frame>
    <description>The percentage of participants with fever (&gt;=102.2 °F oral equivalent) will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measles-like, Rubella-like, Varicella-like Rashes, and Mumps-like Symptoms after Vaccination 1</measure>
    <time_frame>Up to 42 days after Vaccination 1</time_frame>
    <description>The percentage of participants with measles-like rashes, rubella-like rashes, varicella-like rashes, and mumps-like symptoms will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measles-like, Rubella-like, Varicella-like Rashes, and Mumps-like Symptoms after Vaccination 2</measure>
    <time_frame>Up to 42 days after Vaccination 2</time_frame>
    <description>The percentage of participants with measles-like rashes, rubella-like rashes, varicella-like rashes, and mumps-like symptoms will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Solicited Injection-site Erythema, Injection-site Swelling, and Injection-site Pain/Tenderness after Vaccination 1</measure>
    <time_frame>Up to 5 days after Vaccination 1</time_frame>
    <description>The percentage of participants with solicited (Vaccine Report Card) injection-site erythema, injection-site swelling, and injection-site pain/tenderness will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Solicited Injection-site Erythema, Injection-site Swelling, and Injection-site Pain/Tenderness after Vaccination 2</measure>
    <time_frame>Up to 5 days after Vaccination 2</time_frame>
    <description>The percentage of participants with solicited (Vaccine Report Card) injection-site erythema, injection-site swelling, and injection-site pain/tenderness will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Up to 42 days after any vaccination</time_frame>
    <description>The percentage of participants with one or more adverse events will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious Adverse Events</measure>
    <time_frame>Up to 180 days after vaccination 2 (up to 285 days)</time_frame>
    <description>The percentage of participants with one or more serious adverse events will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Varicella Zoster Virus (VZV) Antibody Seroconversion Rate</measure>
    <time_frame>6 weeks (43 days) after Vaccination 1</time_frame>
    <description>The percentage of participants with VZV antibody levels &gt;=1.25 gpELISA units/mL will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Varicella Zoster Virus (VZV) Antibody Geometric Mean Fold Rise from Baseline</measure>
    <time_frame>Baseline and 6 weeks (43 days) after Vaccination 1</time_frame>
    <description>The geometric mean fold rise from Baseline in VZV antibody titer will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Varicella Zoster Virus (VZV) Antibody Geometric Mean Fold Rise from Baseline &gt;=4-fold</measure>
    <time_frame>Baseline and 6 weeks (43 days) after Vaccination 1</time_frame>
    <description>The percentage of participants with geometric mean fold rise from Baseline in VZV antibody titer &gt;=4-fold will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vaccine-related Adverse Events</measure>
    <time_frame>Up to 42 days after any vaccination</time_frame>
    <description>The percentage of participants with one or more vaccine-related adverse events will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vaccine-related Serious Adverse Events</measure>
    <time_frame>Up to 180 days after vaccination 2 (up to 285 days)</time_frame>
    <description>The percentage of participants with one or more vaccine-related serious adverse events will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Study Discontinuations due to an Adverse Event</measure>
    <time_frame>Up to 42 days after any vaccination</time_frame>
    <description>The percentage of participants discontinued from the study due to an adverse event will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Unsolicited Injection-site Adverse Events</measure>
    <time_frame>Up to 42 days after Vaccination 1 and Vaccination 2 (up to 133 days)</time_frame>
    <description>The percentage of participants with one or more unsolicited injection-site adverse events will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Unsolicited Injection-site Reactions</measure>
    <time_frame>Up to 42 days after Vaccination 1 and Vaccination 2 (up to 133 days)</time_frame>
    <description>The percentage of participants with unsolicited (Vaccine Report Card) injection-site reactions will be assessed.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Varicella</condition>
  <arm_group>
    <arm_group_label>VARIVAX™ PE34 Process + M-M-R II™</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VARIVAX™ Passage Extension (PE34) Process vaccine 0.5 mL administered in the left arm or thigh and M-M-R II™ vaccine 0.5 mL administered in the right arm or thigh by subcutaneous injection on Day 1 and Day 91</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VARIVAX™ 2016 Commercial Process + M-M-R II™</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>VARIVAX™ 2016 Commercial Process vaccine 0.5 mL administered in the left arm or thigh and M-M-R II™ vaccine 0.5 mL administered in the right arm or thigh by subcutaneous injection on Day 1 and Day 91</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>VARIVAX™ PE34 Process</intervention_name>
    <description>Varicella virus vaccine live manufactured with a new passage extension process (PE34)</description>
    <arm_group_label>VARIVAX™ PE34 Process + M-M-R II™</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>VARIVAX™ 2016 Commercial Process</intervention_name>
    <description>Varicella virus vaccine live manufactured with the 2016 commercial process</description>
    <arm_group_label>VARIVAX™ 2016 Commercial Process + M-M-R II™</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>M-M-R II™</intervention_name>
    <description>Measles, Mumps, and Rubella virus vaccine live</description>
    <arm_group_label>VARIVAX™ PE34 Process + M-M-R II™</arm_group_label>
    <arm_group_label>VARIVAX™ 2016 Commercial Process + M-M-R II™</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Negative clinical history for varicella, herpes zoster, measles, mumps, and rubella

        Exclusion Criteria:

          -  Received any measles, mumps, rubella, or varicella vaccine at any time prior to the
             study, or is anticipated to receive any of these vaccines outside the study

          -  Any congenital or acquired immune deficiency, neoplastic disease, or depressed
             immunity

          -  Received systemic immunomodulatory steroids within 3 months prior to entering the
             study or is expected to receive them during the course of the study

          -  History of allergy or anaphylactic reaction to neomycin, gelatin, sorbitol, egg
             proteins, chicken proteins, or any component of VARIVAX™ or M-M-R II™

          -  Has any blood dyscrasias, leukemia, lymphoma, or other malignant neoplasm affecting
             the bone marrow or lymphatic systems

          -  Received salicylates within 14 days prior to study vaccination

          -  Exposed to varicella, herpes zoster, measles, mumps, or rubella in the 4 weeks prior
             to study vaccination

          -  Received immune globulin, a blood transfusion, or blood-derived products within 5
             months prior to study vaccination

          -  History of seizure disorder, including febrile seizure

          -  Fever illness (&gt;=102.2 °F [39.0 °C] within 72 hours prior to study vaccination

          -  History of thrombocytopenia

          -  Born to a human immunodeficiency virus (HIV)-infected mother

          -  Has a diagnosis of active untreated tuberculosis

          -  Participated in any other clinical trial (other than a surveillance study) within 30
             days prior to study enrollment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Months</minimum_age>
    <maximum_age>23 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Toll Free Number</last_name>
    <phone>1-888-577-8839</phone>
    <email>Trialsites@merck.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Alabama Clinical Therapeutics ( Site 0018)</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>205-933-8522</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Clinic of Jonesboro, PA ( Site 0030)</name>
      <address>
        <city>Jonesboro</city>
        <state>Arkansas</state>
        <zip>72401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>870-935-6012</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Southland Clinical Research Center ( Site 0017)</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92804</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>714-952-4147</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Premier Health Research Center, LLC ( Site 0044)</name>
      <address>
        <city>Downey</city>
        <state>California</state>
        <zip>90240</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>562-904-2123</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>California Research Foundation ( Site 0003)</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>619-291-2321</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>IMMUNOe Research Centers ( Site 0046)</name>
      <address>
        <city>Thornton</city>
        <state>Colorado</state>
        <zip>80233</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>303-224-4673</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Research at Altamonte Pediatric Associates ( Site 0040)</name>
      <address>
        <city>Lake Mary</city>
        <state>Florida</state>
        <zip>32746</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>407-831-6200</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of South Florida ( Site 0042)</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>813-259-8712</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Advanced Clinical Research ( Site 0038)</name>
      <address>
        <city>Meridian</city>
        <state>Idaho</state>
        <zip>83642</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>208-377-8653</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Heartland Research Associates, LLC ( Site 0029)</name>
      <address>
        <city>Augusta</city>
        <state>Kansas</state>
        <zip>67010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>316-260-8822</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Heartland Research Associates, LLC ( Site 0015)</name>
      <address>
        <city>Newton</city>
        <state>Kansas</state>
        <zip>67114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>316-804-7304</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cotton O'Neil Research Center ( Site 0014)</name>
      <address>
        <city>Topeka</city>
        <state>Kansas</state>
        <zip>66604</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>785-354-9591</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kentucky Pediatric/Adult Research Inc ( Site 0012)</name>
      <address>
        <city>Bardstown</city>
        <state>Kentucky</state>
        <zip>40004</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>502-349-1569</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Louisville: Pediatric Clinical Trials Unit ( Site 0025)</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>502-852-3774</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>ACC Pediatric Research ( Site 0041)</name>
      <address>
        <city>Haughton</city>
        <state>Louisiana</state>
        <zip>71037</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>318-949-0539</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Center For Pharmaceutical Research PC ( Site 0011)</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>816-943-0770</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Child Health Care Associates ( Site 0045)</name>
      <address>
        <city>East Syracuse</city>
        <state>New York</state>
        <zip>13057</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>315-464-5102</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Blue Ridge Pediatric &amp; Adolescent Medicine ( Site 0001)</name>
      <address>
        <city>Boone</city>
        <state>North Carolina</state>
        <zip>28607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>828-262-0100</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ford, Simpson, Lively &amp; Rice Pediatrics, PLLC ( Site 0037)</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>336-768-8062</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Senders Pediatrics ( Site 0034)</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44121</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>216-291-9210</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ohio Pediatric Research Association ( Site 0035)</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45414</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>937-236-5396</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kid's Way Pediatrics ( Site 0047)</name>
      <address>
        <city>Hermitage</city>
        <state>Pennsylvania</state>
        <zip>16148</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>724-981-1219</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Palmetto Pediatrics, PA ( Site 0023)</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29406</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>843-797-5600</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Coastal Pediatric Research ( Site 0006)</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29414</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>843-518-5642</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Holston Medical Group Pediatrics ( Site 0024)</name>
      <address>
        <city>Kingsport</city>
        <state>Tennessee</state>
        <zip>37660</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>423-230-2421</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Benchmark Research ( Site 0005)</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>512-478-5416</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Texas Medical Branch at Galveston ( Site 0032)</name>
      <address>
        <city>Galveston</city>
        <state>Texas</state>
        <zip>77555</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>409-772-1444</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>West Houston Clinical Research Services ( Site 0009)</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77055</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>281-738-2642</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pediatric Healthcare of Northwest Houston ( Site 0027)</name>
      <address>
        <city>Tomball</city>
        <state>Texas</state>
        <zip>77375</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>281-517-0550</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tanner Clinic ( Site 0010)</name>
      <address>
        <city>Layton</city>
        <state>Utah</state>
        <zip>84041</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>801-773-4840</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wee Care Pediatrics-Roy ( Site 0043)</name>
      <address>
        <city>Roy</city>
        <state>Utah</state>
        <zip>84067</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>801-773-8644</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>J Lewis Research Inc / Foothill Family Clinic ( Site 0016)</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>801-554-0158</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>J Lewis Research Inc/Foothill Family Clinic South ( Site 0004)</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84121</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>801-554-0158</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>J Lewis Research Inc/Jordan River Family Medicine ( Site 0019)</name>
      <address>
        <city>South Jordan</city>
        <state>Utah</state>
        <zip>84095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>801-676-8109</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wee Care Pediatrics ( Site 0036)</name>
      <address>
        <city>Syracuse</city>
        <state>Utah</state>
        <zip>84075</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>801-773-8644</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Advanced Clinical Research ( Site 0020)</name>
      <address>
        <city>West Jordan</city>
        <state>Utah</state>
        <zip>84088</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>801-542-8190</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pediatric Research of Charlottesville, LLC ( Site 0039)</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22902</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>434-872-9384</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 1, 2017</study_first_submitted>
  <study_first_submitted_qc>August 1, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 4, 2017</study_first_posted>
  <last_update_submitted>March 7, 2018</last_update_submitted>
  <last_update_submitted_qc>March 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

